06/01/22 6:00 AMNasdaq : SNOA covid-19low floatSonoma Pharmaceuticals and MicroSafe Group DMCC Announce that U.S. EPA has Added Nanocyn® Hospital-Grade Disinfectant to List N for Use Against COVID-19Sonoma Pharmaceuticals, Inc., a global healthcare leader developing and producing patented Microcyn ® technology-based stabilized hypochlorous acid products for a wide range of applications, including wound, eye, oral and nasal care, dermatological conditions and disinfectant use, and its partner, the MicroSafe Group DMCC, are pleased to announce that...RHEA-AIpositive
05/03/22 6:00 AMNasdaq : SNOA low floatSonoma Pharmaceuticals and MicroSafe Group DMCC Announce EPA Approval for Nanocyn® Hospital-Grade Disinfectant in the U.S.Sonoma Pharmaceuticals, Inc., a global healthcare leader developing and producing patented Microcyn ® technology-based stabilized hypochlorous acid products for a wide range of applications, including wound, eye, oral and nasal care, dermatological conditions and disinfectant use, and its partner, the MicroSafe Group DMCC, received EPA approval for...RHEA-AIvery positive
03/30/22 6:00 AMNasdaq : SNOA low floatSonoma Pharmaceuticals Launches New Urinary Tract Infection Product Through Distributors in New Zealand, Australia and South AfricaSonoma Pharmaceuticals, Inc., a global healthcare leader developing and producing patented Microcyn ® technology based stabilized hypochlorous acid products for a wide range of applications, including wound, eye, oral and nasal care, and dermatological conditions, today announced that it has launched Microdox ®, an urinary tract infection catheter and...RHEA-AIneutral
02/11/22 4:30 PMNasdaq : SNOA earningslow floatSonoma Pharmaceuticals Reports Third Quarter FY 2022 Financial ResultsSonoma Pharmaceuticals, Inc., a global healthcare leader developing and producing stabilized hypochlorous acid products for a wide range of applications, including wound care, eye care, nasal care, oral care and dermatological conditions today announced financial results for its third fiscal quarter and nine months ended December 31, 2021.RHEA-AIneutral
01/20/22 4:40 PMNasdaq : SNOA low floatSonoma Pharmaceuticals Announces Expansion of its Partner Network for Oral and Dental Products in the U.S. and ChinaSonoma Pharmaceuticals, Inc., a global healthcare leader developing and producing patented Microcyn ® technology-based stabilized hypochlorous acid products for a wide range of applications, including wound, eye, oral and nasal care, disinfectant use and dermatological conditions, today announced that it has added Salus Medical as an additional...RHEA-AIvery positive
01/05/22 4:55 PMNasdaq : SNOA conferenceslow floatSonoma Pharmaceuticals to Present at H.C. Wainwright BioConnect Virtual Conference January 10-13, 2022Sonoma Pharmaceuticals, Inc., a global healthcare leader developing and producing stabilized hypochlorous acid products for a wide range of applications, including wound care, eye care, nasal care, oral care and dermatological conditions, today announced that it will be featured as a presenting company at the H.C. Wainwright BioConnect Conference.RHEA-AIneutral
11/15/21 8:00 AMNasdaq : SNOA earningslow floatSonoma Pharmaceuticals Reports Second Quarter FY 2022 Financial ResultsSonoma Pharmaceuticals, Inc., a global healthcare leader developing and producing stabilized hypochlorous acid products for a wide range of applications, including wound care, eye care, nasal care, oral care and dermatological conditions today announced financial results for its second fiscal quarter and six months ended September 30, 2021.RHEA-AIneutral
11/09/21 7:00 AMNasdaq : SNOA partnershiplow floatSonoma Pharmaceuticals and Dyamed Biotech Announce Expanded Long-Term Partnership for New Territories and Products in Southeast AsiaSonoma Pharmaceuticals, Inc., a global healthcare leader developing and producing stabilized hypochlorous acid products for a wide range of applications, including wound care, eye care, nasal care, oral care, dermatological conditions and disinfectant use, and its long-time partner, Dyamed Biotech Pte Ltd., announce a renewed and expanded long-term...RHEA-AIvery positive
10/15/21 7:00 AMNasdaq : SNOA covid-19low floatSonoma Pharmaceuticals and MicroSafe Group Announce that Nanocyn® Disinfectant & Sanitizer Has Been Approved by the Australia TGA with a 15 Second SARS-CoV-2 (COVID-19) Kill TimeSonoma Pharmaceuticals, Inc., a global healthcare leader developing and producing stabilized hypochlorous acid products for a wide range of applications, including wound care, eye care, nasal care, oral care, dermatological conditions and disinfectant use, and its partner, the MicroSafe Group, announce that the Australian Therapeutic Goods Administration...RHEA-AIneutral
09/28/21 7:00 AMNasdaq : SNOA low floatSonoma Pharmaceuticals Launches Its First Over-the-Counter Products in the U.S. on Amazon and a New Consumer-Focused Product on Amazon in EuropeSonoma Pharmaceuticals, Inc., a global healthcare leader developing and producing stabilized hypochlorous acid products for a wide range of applications, including wound care, eye care, nasal care, oral care, and dermatological conditions, today announced the over-the-counter consumer launch of Regenacyn ® Advanced Scar Gel and Ocucyn ® Eyelid& Eyelash...RHEA-AIpositive